Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial

Abstract

Introduction This MONONOFU trial subgroup analysis evaluates the efficacy of lasmiditan across patient and migraine characteristics in Japanese patients with migraine. Methods MONONOFU trial was a multicenter, randomized, double-blind, placebo-controlled study. The patients were randomly assigned in a 3:7:6:7 ratio to receive lasmiditan 50 mg, 100 mg, 200 mg, or placebo for a single migraine attack within 4 h of pain onset. Efficacy of lasmiditan vs placebo was evaluated at 2 h post dose for proportion of patients with headache pain freedom. Efficacy was assessed across patient characteristics (age, sex, body weight, cardiovascular risk factors (CVRF), and comorbidity of tension-type headache), migraine disease characteristics (history of migraine with aura, migraine prevention therapy, triptan response, and triptan use or nonuse), and migraine attack characteristics (headache severity, aggressive headache, attack during perimenstrual period, time to dosing, time of dosing, experienced treatment-emergent adverse event (TEAE) of dizziness, and experienced TEAE of somnolence). Logistic regression was used; all subgroup analyses were not analyzed with multiplicity-adjusted statistical tests. Results Treatment-by-subgroup interactions (by each arm) were not significant ( p ≥ 0.05) for pain freedom at 2 h post dose across all patient subgroups and lasmiditan doses, except for CVRF (100 mg and 200 mg), migraine with aura (50 mg), triptan response (50 mg), and time to dosing (200 mg). Treatment-by-subgroup interactions (by overall) were not significant ( p ≥ 0.05) for pain freedom at 2 h post dose across all patient subgroups, except for CVRFs. Higher proportions of patients were pain free at 2 h post dose when treated with lasmiditan (50 mg, 100 mg, and 200 mg) versus placebo, irrespective of most patient characteristics, migraine disease characteristics, and migraine attack characteristics. Conclusion Although few interactions were observed, lasmiditan could be a promising acute treatment option in a wide range of Japanese patients with migraine, as efficacy is not generally influenced by patient and migraine characteristics. Supplementary Information The online version contains supplementary material available at 10.1007/s12325-022-02304-0.

Nano Parthenolide Improves Intestinal Barrier Function of Sepsis by Inhibiting Apoptosis and ROS via 5-HTR2A

“…Some studies have reported that PTL can prevent migraine by inhibiting 5-HTR2A. 41 This study found that Nano PTL can inhibit the production of cell apoptotic factors, reduce the level of apoptosis, reduce oxidative stress, and play a protective effect on intestinal barrier of sepsis rats by up-regulating the 5-HTR2A.…”

Molecular and Cellular Neurobiology of Circadian and Circannual Rhythms in Migraine: A Narrative Review

“…Preclinical studies have shown that lasmiditan is non-vasoconstrictive and can penetrate the blood–brain barrier to reach the central nervous system [ 94 ]. Lasmiditan has been shown to be effective in the acute treatment of migraines in randomized, double-blind, placebo-controlled clinical trials [ 95 , 96 , 97 , 98 ]. Lasmiditan works by selectively activating 5-HT 1F receptors located in the trigeminal and central nervous systems [ 94 ].…”

“…Lasmiditan is indicated for the acute treatment of migraine attacks, specifically for the relief of moderate to severe headache pain. Clinical studies have shown that lasmiditan is effective in providing freedom from pain and the most troublesome symptoms such as nausea, photophobia, and phonophobia [ 95 , 96 , 97 , 98 ]. Common side effects of lasmiditan include dizziness, fatigue, paresthesia, and sedation, which may lead to central nervous system depression.…”

Profile of Lasmiditan in the Acute Treatment of Migraine in Adults: Design, Development, and Place in Therapy

“…26 Post-hoc analysis demonstrated that there were no significant differences in patient characteristics or migraine characteristics with regard to efficacy of the 50 mg, 100 mg, 200 mg doses and that the 200 mg dose appeared to be the most efficacious in this study population. 27…”